Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Journal of Experimental Hematology ; (6): 1419-1423, 2011.
Article in Chinese | WPRIM | ID: wpr-261856

ABSTRACT

The study was purposed to detect BAFF/APRIL gene expression changes in bone marrow mononuclear cells (BMMNC) and myeloma cell line U266 after interference with glucocorticoid and bortezomib. After separation of BMMNC from 7 patients with multiple myeloma, BAFF/APRIL mRNA expression in BMMNC and U266 cell line was detected by real-time PCR after treated with dexamethasone 100, 200 µg/ml, methylprednisolone 100, 200 µg/ml, bortezomib 0.1 µg/ml alone and dexamethasone or methylprednisolone combined with bortezomib respectively for 48 hours. The results showed that U266 cells and BMMNC of untreated MM patients highly expressed BAFF/APRIL genes. When dexamethasone, methylprednisolone or bortezomib was added to U266 cells or BMMNC alone, BAFF/APRIL gene expression decreased as compared with the blank control (p < 0.01). The inhibiting effect of bortezomib to BAFF/APRIL expression was obviously strong(p < 0.05). When dexamethasone or methylprednisolone combined with bortezomib, the BAFF/APRIL gene expression further decreased compared with dexamethasone or methylprednisolone alone (p < 0.01). As compared with the group of methylprednisolone combined with bortezomib, BAFF/APRIL gene expression decreased in dexamethasone combined with bortezomib with a statistically significant difference (p < 0.05). It is concluded that the expression of BAFF/APRIL gene is down-regulated after bing treated with glucocorticoids and bortezomib, which suggests that besides the glucocorticoid receptor and proteasomes targets, BAFF/APRIL and their receptor sites may be new targets of glucocorticoids and bortezomib.


Subject(s)
Humans , B-Cell Activating Factor , Genetics , Metabolism , Boronic Acids , Pharmacology , Bortezomib , Cell Line, Tumor , Gene Expression Regulation, Neoplastic , Glucocorticoids , Pharmacology , Multiple Myeloma , Metabolism , Pyrazines , Pharmacology , RNA, Messenger , Genetics , Tumor Necrosis Factor Ligand Superfamily Member 13 , Genetics , Metabolism
2.
Journal of Central South University(Medical Sciences) ; (12): 131-133, 2006.
Article in Chinese | WPRIM | ID: wpr-813749

ABSTRACT

OBJECTIVE@#To understand the clinical features and histopathology of histocytic necrotizing lymphadenitis (HNL) so as to better recognize the disease.@*METHODS@#The clinical features, histopathology, and diagnosis of 10 patients admitted to our hospital were retrospectively analyzed.@*RESULTS@#The clinical features of these 10 cases included: young females were the majority; lymphadenopathy and fever were the most common clinical manifestations; some cases were accompanied by connective tissue diseases. Histopathologic examination showed distinctive necrosis and around the necrotic foci, variable proliferations of histocytes but generally without infiltration of neutrophils.@*CONCLUSION@#HNL has some typical histopathological alterations and relatively fine prognosis,but it tends to be misdiagnosed as lymphoma or lymphoid tuberculosis and may be accompanied by other diseases.


Subject(s)
Adolescent , Adult , Female , Humans , Male , Middle Aged , Age Factors , Diagnosis, Differential , Histiocytic Necrotizing Lymphadenitis , Diagnosis , Pathology , Lymph Nodes , Pathology , Lymphoma , Diagnosis , Retrospective Studies , Sex Factors , Tuberculosis, Lymph Node , Diagnosis
3.
Journal of Central South University(Medical Sciences) ; (12): 222-227, 2006.
Article in Chinese | WPRIM | ID: wpr-813729

ABSTRACT

OBJECTIVE@#To explore KM3 multiple myeloma (MM) cell line specific cytotoxic T lymphocyte (CTL) response in vitro mediated by autologous dendritic cells (DCs) aroused by KM3 cells' lysates and acid-eluted peptides.@*METHODS@#Monocytes were isolated from the peripheral blood of healthy individuals and MM patients, and were cultured in serum medium with IL-4, GM-CSF, and TNF-alpha to generate DCs. These DCs were pulsed by KM3 cells' lysates or the acid-eluted peptides, then incubated with autologous T lymphocytes for 3 days to induce KM3 cell antigen specific CTL. MTT assay was performed to examine the specific KM3 cells' lysing ability of CTL.@*RESULTS@#DCs were generated in peripheral blood monocytes cultured in the serum medium containing GM-CSF, IL-4, and TNF-alpha. Autologous T lymphocytes induced by IL-2 and DCs pulsed with KM3 cells' lysates or the acid-eluted peptides showed strong killing effect on KM3 cells.@*CONCLUSION@#The DCs pulsed by KM3 cells' lysates or the acid-eluted peptides incubated with autologous T lymphocytes can induce KM3 cell antigen specific CTL.


Subject(s)
Humans , Cells, Cultured , Dendritic Cells , Allergy and Immunology , Granulocyte-Macrophage Colony-Stimulating Factor , Pharmacology , Interleukin-4 , Pharmacology , Monocytes , Cell Biology , Multiple Myeloma , Allergy and Immunology , Pathology , T-Lymphocytes , Cell Biology , T-Lymphocytes, Cytotoxic , Allergy and Immunology , Tumor Cells, Cultured
4.
Journal of Central South University(Medical Sciences) ; (12): 68-71, 2005.
Article in Chinese | WPRIM | ID: wpr-813472

ABSTRACT

OBJECTIVE@#To investigate the clinical significance of the changes of vascular endothelial growth factor ( VEGF ) and interleukin-6 ( IL-6 ) level in multiple myeloma (MM), solid tumor following bone metastasis.@*METHODS@#Thirty- seven MM patients, including 7 in Stage I , 8 in Stage II , 22 in Stage III, 8 solid tumor with bone metastasis patientsly, and 17 healthy controls were enrolled in this study. The serum VEGF and IL-6 levels were determined by ELISA.@*RESULTS@#Serum VEGF and IL-6 concentrations in patients with MM and solid tumor were significantly higher than those of the healthy controls (P <0.01 ), and the VEGF level was higher in MM than in solid tumor with bone metastasis. There was significant difference in VEGF and IL-6 levels in various clinical stages of MM. VEGF levels in Stage II were significantly higher than in Stage I (P < 0.05 ) and IL-6 levels in Stage II were significantly higher than in Stage I (P < 0.05). The levels of IL-6 showed great difference according to bone lesion scores (P < 0.05). There was a positive correlation between IL-6 and serum calcium or C-reactive protein( P <0.01) , and there was a positive correlation between VEGF and serum Cr or urinary Bene-Jones protein lambda (P < 0.01 ). The IL-6 levels had significant differences between patients with the normal serum CRP, serum calcium, and beta2-MG and patients with abnormal ones (P < 0.05). VEGF levels showed significant differences between the patients with normal serum Cr, serum calcium Bene-Jones protein lambda, and urinary Bene-Jones protein lambda and patients with abnormal ones (P < 0.05).@*CONCLUSION@#Serum VEGF and IL-6 levels are helpful to diagnose the clinical stages, and understand bone lesion and serevity of MM.


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Biomarkers , Blood , Enzyme-Linked Immunosorbent Assay , Interleukin-6 , Blood , Multiple Myeloma , Blood , Vascular Endothelial Growth Factor A , Blood
5.
Chinese Medical Journal ; (24): 808-812, 2004.
Article in English | WPRIM | ID: wpr-284902

ABSTRACT

<p><b>BACKGROUND</b>We determined the diagnosis of hereditary hemorrhagic telangiectasis (HHT) in a suspected HHT family, identified ALK1 gene mutation and established a gene diagnosis method of HHT. The level of related plasma proteins (transforming growth factor beta and thrombomodulin) were also analyzed.</p><p><b>METHODS</b>Bleeding history and family history were collected; Dilatant nasal mucosal capillaries in proband were observed under nasal cavity endoscope; exons 3, 7, 8 of ALK1 gene in proband and her family members were amplified with polymerase chain reaction (PCR), and the PCR products were analyzed. Using enzyme-linked immunosorbent assay (ELISA), plasma TGF-beta1 and TGF-beta2 concentrations were measured. Plasma thrombomodulin (TM) level was detected by Western blotting.</p><p><b>RESULTS</b>Of all family members, four had epstaxis, two had evident telangiectases on skin or mucosa. Gene screening results showed that C to T substitution at position 1231 in exon 8 of ALK1 gene (CGG-->TGG) existed in proband, her affected brother and their father. The mutation did not exist in proband's sister-in-law and nephew. Plasma TGF-beta1 concentrations in the affected HHT was 20,538, 17,194, 13,131 pg/ml, while that of normal control and unaffected family members was 15,950, 20,297, 12,836 pg/ml, respectively. Plasma TGF-beta2 in HHT patients was 14,502, 9550, 10,592 and that of normal controls 8579, 20,297, 7680 pg/ml respectively. Level of plasma TM was in HHT subjects significantly lower than in normal subjects.</p><p><b>CONCLUSIONS</b>Chinese HHT individuals have mutant ALK1 gene, a C1231T variation on exon 8 of ALK1 is responsible for HHT clinical phenotypes in this family. ALK1 gene analysis, together with special clinical phenotypes and family history, provides a reliable method in diagnosing HHT. In affected HHT subjects, plasma TGFbeta levels were not obviously different from those of normal subject; while plasma TM concentration was significantly lower than that in normal subjects. The significance and mechanism remain to be elucidated.</p>


Subject(s)
Aged , Female , Humans , Male , Middle Aged , Activin Receptors, Type I , Genetics , Activin Receptors, Type II , Asian People , Genetics , China , Mutation , Telangiectasia, Hereditary Hemorrhagic , Blood , Genetics , Thrombomodulin , Blood , Transforming Growth Factor beta , Blood
SELECTION OF CITATIONS
SEARCH DETAIL